Full-Time

Director Project Management Office

PMO

Updated on 9/4/2026

LOTTE BIOLOGICS

LOTTE BIOLOGICS

501-1,000 employees

GMP CDMO for biologics and ADCs

Compensation Overview

$155k - $220k/yr

+ 23% target bonus

East Syracuse, NY, USA

In Person

Onsite role with up to 10–15% travel for client, global PMO, training, and cross-site meetings.

Bachelor's

Category
Project & Program Management (1)
Required Skills
Power BI
Risk Management

Get referred to LOTTE BIOLOGICS

See people who can refer or advise you

Requirements
  • A bachelor's degree in Engineering, Life Sciences, Business, or a related field is required.
  • At least 12 years of relevant experience, including significant experience in the biopharmaceutical and/or contract development and manufacturing organization industry, is required.
  • Significant leadership experience in project management, program or alliance management, PMO leadership, and/or related operational leadership roles supporting complex biologics programs is required.
  • Demonstrated success leading complex current Good Manufacturing Practice manufacturing, technical transfer, and/or end-to-end client programs within a contract development and manufacturing environment is required.
  • Experience establishing, leading, or enhancing PMO governance frameworks, portfolio management processes, and performance reporting mechanisms is required.
  • Experience leading direct reports and developing talent within a matrixed, cross-functional organization is required.
  • Demonstrated success influencing senior leaders, clients, and cross-functional stakeholders to drive decisions, alignment, and business outcomes is required.
  • Strong experience managing client relationships, governance forums, and complex project communications at a strategic level is required.
  • Deep knowledge of project and portfolio management methodologies, risk management practices, and governance models within a biopharmaceutical or contract development and manufacturing organization environment is required.
  • Strong understanding of biologics manufacturing, process and analytical technical transfer, current Good Manufacturing Practice operations, and regulatory requirements in Good Practice settings is required.
  • Strong business and financial acumen, including understanding of project forecasting, cost management, invoicing processes, change impact assessment, and client financial visibility, is required.
  • Ability to translate business strategy and operational priorities into PMO governance, execution plans, and measurable outcomes is required.
  • Demonstrated ability to influence senior leaders, clients, and cross-functional stakeholders across a matrixed organization is required.
  • Strong people leadership skills, including coaching, performance management, organizational development, and capability building, are required.
  • Ability to lead through ambiguity, manage competing priorities, and drive resolution of complex operational and portfolio issues is required.
  • Excellent communication, presentation, negotiation, and stakeholder management skills, including executive-level communication, are required.
  • Proficiency with Microsoft Project, Smartsheet, Power BI, and other project and portfolio management tools is required.
  • Ability to balance strategic leadership with appropriate operational involvement to support execution and business outcomes is required.
  • The role requires the ability to wear required personal protective equipment when entering controlled manufacturing or laboratory environments.
  • The role requires the ability to occasionally lift or carry materials weighing up to 15 pounds.
Responsibilities
  • Lead the PMO function for the Syracuse Bio Campus, including functional priorities, governance standards, operating mechanisms, and talent development.
  • Translate site, functional, and business objectives into PMO strategies, priorities, and execution frameworks supporting client programs and internal strategic initiatives.
  • Partner with the Vice President of Global PMO to align site PMO objectives with global strategy, governance standards, reporting expectations, and continuous improvement priorities.
  • Establish and sustain PMO frameworks, processes, tools, and performance measures across the project portfolio.
  • Serve as a strategic partner to site leadership by identifying risks, opportunities, resource needs, and operational tradeoffs affecting project delivery and business performance.
  • Influence PMO best practices across the global network through partnership, knowledge sharing, and adoption of scalable standards.
  • Provide leadership and oversight for Syracuse client projects and key internal initiatives against scope, timelines, financial commitments, quality requirements, and customer expectations.
  • Direct portfolio governance processes, including project reviews, milestone assessments, escalation management, portfolio reporting, and decision-support mechanisms.
  • Embed risk management, issue escalation, and mitigation planning within project execution.
  • Drive portfolio visibility through governance, key performance indicator reporting, lessons learned, and performance reviews.
  • Lead PMO engagement in complex client-facing programs, including end-to-end contract development and manufacturing organization projects involving cell line development, linker-payload, drug substance, drug product, and technical transfer activities.
  • Implement improvements to PMO effectiveness, including governance, reporting, prioritization, resource planning, and organizational capability.
  • Serve as a senior PMO representative and liaison for client stakeholders throughout the project lifecycle.
  • Lead or participate in Joint Steering Committee meetings and other client governance forums, providing updates on program status, risks, financials, scope changes, and milestones.
  • Partner with Business Development, Development, and Operations on new business opportunities, project onboarding, technical transfers, change controls, and client program success.
  • Manage project scope, change orders, and program communications in alignment with contractual, operational, and financial objectives.
  • Support business growth by creating delivery models, governance approaches, and cross-functional plans for new and expanding client programs.
  • Lead PMO financial oversight for client programs and the function, including forecasting, budget management, invoicing alignment, change impact visibility, and cost control.
  • Provide site and senior leadership with visibility into project financials, milestones, risks, constraints, and operational implications.
  • Partner with site leadership and cross-functional stakeholders on capacity planning, prioritization, and resource allocation.
  • Drive operational discipline and accountability by linking project performance to business, financial, and customer outcomes.
  • Coordinate resolution of complex project and portfolio challenges across functions and competing priorities.
  • Lead, develop, and coach a team of project managers responsible for client project execution.
  • Set expectations, performance standards, and development priorities for the PMO team.
  • Build PMO organizational capability through mentoring, succession planning, knowledge sharing, and professional development.
  • Foster a high-performing team culture grounded in collaboration, inclusion, ownership, client focus, and continuous improvement.
  • Lead through direct people management and matrix influence to align teams, resolve conflict, and drive execution.
  • Lead, develop, and manage PMO team members, including hiring, performance management, and coaching.
  • Oversee resource planning and allocation for program and project delivery.
  • Establish goals, accountability, and performance expectations aligned to organizational priorities.
  • Promote adoption of PMO standards and best practices.
  • Provide guidance and mentorship to strengthen project management capabilities across the organization.
Desired Qualifications
  • An advanced degree is preferred.
  • PMP certification or an equivalent certification is preferred.

LOTTE BIOLOGICS provides GMP manufacturing services for biopharmaceuticals, operating a Syracuse, NY campus with a total bioreactor capacity of 40,000 L (eight 5,000 L stainless steel bioreactors) and extensive QC labs and warehousing, supported by regulatory approvals worldwide. The company is expanding into Antibody-Drug Conjugates (ADC) with on-site drug substance production and conjugation, backed by over $100 million invested in ADC modalities, offering an end-to-end service from drug substance manufacturing to ADC conjugation. Looking ahead, it is constructing three advanced bio plants in Songdo, South Korea, each with eight 15,000 L bioreactors plus additional 3,000 L units to support clinical production, aiming for a combined bioreactor capacity exceeding 360,000 L. The overall goal is to become a top-tier global CDMO in the biopharmaceutical industry, delivering therapies to patients worldwide.

Company Size

501-1,000

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$214.1M

Headquarters

Seoul, South Korea

Founded

N/A

Get referred to LOTTE BIOLOGICS

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 G-SEED Excellent rating supports Songdo credibility before GMP and commercial launches.
  • May 18, 2026 Ottimo expansion and April 6 Japan deal show active customer wins.
  • July 2026 capital raise funded construction despite backlog reaching $564.7 million in Q1.

What critics are saying

  • July 2026 losses stayed severe: 2024 operating loss 132.6 billion won, Q1 loss 56.2.
  • Seven capital raises since 2022 signal dependence on Lotte Group support, not self-funding.
  • If commercial orders lag into 2027, Songdo becomes an underutilized sunk-cost liability.

What makes LOTTE BIOLOGICS unique

  • June 2026 Songdo Plant 1 added 120,000 liters, giving Lotte a Korea-U.S. dual-site CDMO.
  • Asimov partnership delivers 8.5-month DNA-to-DS timelines, compressing early development for global biotechs.
  • Syracuse QC and Songdo commercial manufacturing split clinical and scale-up work across regions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Flexible Work Hours

Target Bonus

Growth & Insights and Company News

Headcount

6 month growth

-15%

1 year growth

-15%

2 year growth

-15%
AdvanceH2
Jul 31st, 2026
Lotte Group transforms business focus toward bio, AI, and hydrogen innovations.

Lotte Group transforms business focus toward bio, AI, and hydrogen innovations. Key points. * Lotte Group is transitioning from petrochemicals to bio, AI, and hydrogen. * A new 120,000-liter antibody drug plant in Incheon is fully operational. * Utilization of AI circuit foil production has significantly increased. * LotteSK Eneroot aims to complete an 80MW hydrogen project by year-end. Lotte Group, a prominent South Korean conglomerate, is steering its core business strategy away from traditional petrochemicals and embracing innovations in bio, artificial intelligence (AI), and hydrogen sectors. This transformation is gaining momentum as the company reports significant developments in these areas throughout 2026. The announcement includes the completion of a major antibody drug manufacturing facility at the Lotte Biologics Songdo Campus in Incheon. This new plant, capable of producing 120,000 liters, features eight state-of-the-art 15,000-liter bioreactors and is poised to play a crucial role in the contract development and manufacturing organization (CDMO) space. It aims to aid pharmaceutical companies in producing drugs more efficiently and is expected to achieve good manufacturing practice (GMP) certification ahead of schedule, which is vital for securing commercial orders. In addition to advancements in biopharmaceuticals, Lotte Group is also seeing a robust demand for high-volume low-profile (HVLP) copper foil used in AI data centers. This demand has led to an increase in production capabilities at their Iksan plant, with plans to expand the output from 3,700 tons to 16,000 tons by 2027. The impressive rise in utilization rates for AI circuit foil production - from 45% to 67% - underscores the growing importance of AI technologies within their business structure. Hydrogen initiatives are also a key component of Lotte's strategic pivot. LotteSK Eneroot, a partnership involving Lotte Chemical and Air Liquide Korea, has made significant strides in the hydrogen power sector. The company has initiated commercial operations of its first 20MW hydrogen power plant in April 2026. This facility supplies byproduct hydrogen from associated companies and uses petrochemical byproducts as fuel for energy production. The overarching objective is to complete a total of 80MW of hydrogen capacity by the end of the year. Furthermore, Lotte Group's expansion is not limited to the energy and biopharmaceutical sectors. The conglomerate has formed a joint venture between its food divisions in Korea and Japan, consolidating operations into a single entity in Singapore to unify decision-making and enhance growth opportunities in Asian markets. This initiative is viewed as a strategic response to slowing domestic market growth, with hopes of leveraging overseas sales to drive revenue. Overall, Lotte Group's strategic shift towards biopharmaceuticals, AI, and hydrogen presents a positive outlook for the company's future, reflecting their commitment to innovation and adaptation in a rapidly changing global economy. July 31, 2026 at 10:11 AM Incheon, South Korea

PR Newswire APAC
Jun 22nd, 2026
LOTTE Biologics completes construction of Songdo Bio Campus Plant 1 and obtains approval for use.

LOTTE Biologics completes construction of Songdo Bio Campus Plant 1 and obtains approval for use. 2026-06-22 08:00 446 INCHEON, South Korea and SAN DIEGO, June 22, 2026 /PRNewswire/ - LOTTE Biologics announced that it has completed major construction and obtained approval for use for Plant 1 at its Songdo Bio Campus in Incheon, South Korea. [Picture] LOTTE Biologics Songdo Bio Campus Factory 1 The milestone was achieved approximately two years after the start of construction in 2024, representing an exceptionally fast project execution timeline among global biologics manufacturing facility construction projects. The approval for use confirms that the physical construction of the facility has been completed, including site development, building and civil engineering works, production equipment, piping, electrical systems, and control systems. As biologics manufacturing facilities must support complex cell culture processes while meeting global cGMP standards, their construction requires advanced design and engineering capabilities as well as systematic quality management. LOTTE Biologics incorporated operational experience and manufacturing know-how from its Syracuse Bio Campus into the construction of Songdo Plant 1. From the design stage, the company implemented an automated Manufacturing Control System, or MCS, to enhance production efficiency and quality competitiveness. The facility has also been designed to maximize the company's ability to provide customized support for customers during future commercial manufacturing. Songdo Plant 1 is a 120,000-liter antibody manufacturing facility, equipped with eight 15,000-liter stainless-steel bioreactors to support large-scale commercial production demand. The facility also incorporates advanced bioprocessing technologies, including higher-titer cell culture and perfusion processes. In addition, LOTTE Biologics introduced an automated warehouse and real-time monitoring-based operating systems to improve manufacturing stability and operational efficiency. Through its dual-site strategy linking Songdo Bio Campus with Syracuse Bio Campus in New York, the United States, LOTTE Biologics is now positioned to provide integrated CDMO services that connect early-stage clinical production with large-scale commercial manufacturing. Under this model, the Syracuse Bio Campus will support early-stage customer projects and clinical supply, while Songdo Plant 1 will serve as a large-scale commercial manufacturing base. This dual-site structure enables the company to respond flexibly to a broad range of customer needs, from small-scale projects to large commercial production volumes. Based on its manufacturing network spanning the United States and Korea, LOTTE Biologics anticipates enhanced support for customers' regional supply strategies and growing demand for supply chain risk diversification. LOTTE Biologics plans to begin full-scale commissioning and production system validation in the second half of this year. Through these efforts, the company aims to secure GMP manufacturing readiness early and establish a stable foundation for commercial manufacturing to meet global customer demand. The company also plans to continue strengthening production efficiency and quality competitiveness through data-driven process operations and advanced digital systems. "Completing major construction and obtaining use approval for Songdo Plant 1 approximately two years after groundbreaking is the result of our employees' capabilities, dedicated project execution, and strategic support and collaboration across the LOTTE Group," said James Park, CEO of LOTTE Biologics. "Based on our global manufacturing platform connecting Syracuse and Songdo, we will establish ourselves as a trusted CDMO partner for customers worldwide." He added, "With an integrated manufacturing system that combines speed, quality, and production flexibility, we will proactively respond to the diverse development and commercialization needs of global customers and continue growing into a world-class CDMO company."

PR Newswire
Jun 22nd, 2026
LOTTE Biologics completes 120,000-litre Songdo plant in two years, links US and Korea sites

LOTTE Biologics has completed construction of Plant 1 at its Songdo Bio Campus in Incheon, South Korea, and obtained approval for use approximately two years after breaking ground in 2024. The 120,000-litre antibody manufacturing facility features eight 15,000-litre stainless-steel bioreactors for large-scale commercial production. It incorporates an automated Manufacturing Control System, advanced bioprocessing technologies, and real-time monitoring systems to enhance efficiency and quality. The facility will work alongside LOTTE Biologics' Syracuse Bio Campus in New York, with Syracuse handling early-stage clinical production and Songdo focusing on large-scale commercial manufacturing. This dual-site strategy enables the company to serve customers across development stages and support regional supply diversification. LOTTE Biologics plans to begin commissioning and validation in the second half of this year.

ValGenesis
Mar 17th, 2026
LOTTE Biologics implements ValGenesis e-Logbook solution to modernize QC operations.

LOTTE Biologics implements ValGenesis e-Logbook solution to modernize QC operations. SANTA CLARA, Calif., March 17, 2026 - ValGenesis, Inc., the global leader in enterprise digital validation and compliance solutions, today announced that LOTTE Biologics, a rapidly growing contract development and manufacturing organization (CDMO) headquartered in Seoul, South Korea, has successfully gone live with the ValGenesis e-Logbook solution. The digital logbook management tool transforms operational execution in regulated environments with complete traceability and control. Founded in 2022, LOTTE Biologics entered the pharmaceutical industry with the ambition of becoming a leading global CDMO. The company operates a Bio Campus in Syracuse, New York, and is nearing completion on the construction of a state-of-the-art Bio Campus in Songdo, South Korea, where it is operating a satellite quality control (QC) lab as a precursor to the main facility. As part of its digital transformation journey, LOTTE Biologics has implemented ValGenesis in its satellite QC lab, with plans to extend the platform across its main laboratory and production facilities in the upcoming Songdo Bio Campus. The go-live represents a major milestone in building a fully digital and connected quality ecosystem across the organization. LOTTE Biologics intends to solidify their digital foundation through the implementation and enhancement of enterprise systems, including LIMS, EAM, and EDMS, to support seamless data flow, strengthen consistency, and improve overall operational efficiency. The company is also exploring instrument data automation via the ValGenesis Gateway, which enables direct data capture from laboratory instruments, reducing manual effort, improving accuracy, and providing real-time insights for faster decision-making. The solution replaces paper-based logbooks with real-time digital forms accessible across devices. It supports QR and barcode-based form selection, offline data capture, and no-code configuration to align with standard operating procedures (SOPs). The ValGenesis e-Logbook system ensures regulatory compliance through role-based access, timestamped audit trails, and automated review workflows, and it delivers enterprise-wide visibility when integrated with MES, QMS, LIMS, and CMMS systems. "This project represents more than just a system implementation - it marks a meaningful transformation for LOTTE Biologics," said Hyunjin Cho, IT Team, LOTTE Biologics. "By replacing paper-heavy QC processes with streamlined digital workflows, we have built a more efficient, reliable, and scalable environment that enhances quality management and prepares us for future growth." "We are proud to partner with LOTTE Biologics on this journey toward digital excellence," said Terrance Blackwell, Chief Delivery Officer at ValGenesis, Inc. "The successful go-live underscores our shared commitment to innovation, data integrity, and operational efficiency. With this milestone, LOTTE Biologics takes an important step toward building a fully digital, automated, and compliant R&D-to-manufacturing ecosystem - supporting its vision to become a global leader in biopharmaceutical development and manufacturing." About LOTTE Biologics LOTTE Biologics is a contract development & manufacturing organization (CMDO) delivering integrated biologics and bioconjugate services across the full product lifecycle. Their capabilities encompass phase-appropriate DS manufacturing for mammalian-cell-based biologics, including monoclonal antibodies, fusion proteins, multi-specifics, and integrated ADC manufacturing. Guided by the vision "Possibilities Beyond Limits," LOTTE Biologics works alongside innovators of all sizes to enable efficient scale-up, dependable execution, and the advancement of transformative therapeutic programs. For more information visit: https://www.lottebiologics.com/en About ValGenesis Inc. ValGenesis, Inc., is the global leader in enterprise digital validation. Serving the life sciences industry for nearly two decades, ValGenesis enables companies to digitize their commissioning, qualification, and validation processes through its AI-enabled ValGenesis Smart GxP(TM) platform, which includes solutions for risk management, cleaning validation, continued process verification, and CMC development. ValGenesis helps customers worldwide reduce costs, improve compliance, and accelerate innovation. For more information visit: https://www.valgenesis.com/ For further information, contact: Althea D'Sylva, ValGenesis Communications, +1 510-445-0505 Ex.1026 [email protected] LOTTE Biologics Media Contacts: Baeklae Jo | [email protected] Sangho Lee | [email protected] Kihong Kim | [email protected]

Webarama
Mar 9th, 2026
LOTTE Biologics to Participate in DCAT Week 2026 in New York to Explore Global Partnership Opportunities

LOTTE Biologics to participate in DCAT Week 2026 in New York to explore global partnership opportunities. March 9, 2026 SEOUL, South Korea, March 9, 2026 /PRNewswire/ - LOTTE Biologics announced today that it will participate in DCAT Week 2026, a global pharmaceutical and biotechnology industry event taking place in New York from March 23 to 26, to explore new partnership opportunities and strengthen its global presence in the contract development and manufacturing organization (CDMO) sector. Held annually in New York, DCAT Week is one of the industry's most prominent global gatherings, bringing together pharmaceutical companies, CDMOs, and other life sciences stakeholders to discuss collaboration opportunities and industry trends. During the event, LOTTE Biologics will host a series of meetings at the Lotte New York Palace Hotel, where DCAT Week is held, to engage with potential partners and explore new business opportunities in the global CDMO market, including North America. The company will highlight the synergy between its Syracuse Bio Campus in New York and the Songdo Bio Campus in Incheon, South Korea, which is scheduled for mechanical completion in August 2026 as part of LOTTE Biologics' plan to expand its global manufacturing network. By leveraging the dual-site model across the United States and Korea, the company aims to support global partners with flexible and reliable manufacturing capabilities. LOTTE Biologics will also emphasize the expansion of its service capabilities through strategic collaborations. In particular, through its ongoing collaboration with the U.S.-based cell line development experts Asimov, the company is able to offer end to end DNA to DS services. This collaboration allows for streamlined, unified capabilities with 8.5 month timelines from transfection to drug substance release. "DCAT Week is an important gathering where key decision-makers across the global pharmaceutical and biotechnology industry come together," said a representative from LOTTE Biologics. "Through this participation, we aim to actively explore partnership opportunities with potential clients and continue strengthening our competitiveness in the global market."